Effect of Colchicine on MMP-9, NOX2, and TGF-β1 in Myocardial Infarct
ST Elevation Myocardial Infarction, Colchicine, Cardiac Remodeling, Ventricular
About this trial
This is an interventional treatment trial for ST Elevation Myocardial Infarction focused on measuring STEMI, Colchicine, MMP-9, NOX2, TGF-beta 1
Eligibility Criteria
Inclusion Criteria: Subjects who presenting with STEMI more than 12 hours from the onset of chest pain Aged 40-70 years Agreed with the informed consent Exclusion Criteria: aged <40 or >70 years subjects that have unstable condition such as comorbid disease (infection, inflammation, malignancy, severe renal failure (EGFR <30), a history of hepatic cirrhosis, acute exacerbation of hepatitis, or severe liver disease, alcoholic patient, cardiac arrest, ventricular fibrillation or cardiogenic shock, unstable hemodynamic) subjects that have colchicine hypersensitivity pregnancy or breastfeed
Sites / Locations
- RSD dr SoebandiRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
Late PCI + Colchicine
Late PCI + Optimal Medical Treatment
Optimal Medical Treatment + Colchicine
Optimal Medical Treatment
Subjects that undergo late PCI (12-48 hours after STEMI), received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate), and colchicine
Subjects that undergo late PCI (12-48 hours after STEMI) and received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate)
Subjects that received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate) and colchicine
Subjects that received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate)